Systemic administration of IL-7–CBD and CBD–IL-12 in conjunction with suboptimal αPD-1 dose showed unprecedented tumor control without any overt toxicity in the autochthonous BrafV600E/Pten−/−/βCATSTA melanoma model. This evidence concerns the gene IL7 and melanoma.